Search Results for: ips cells

Review of Mitalipov Nature paper: cloned ES cells vs iPS cells

NT-ESC

Just how good are human embryonic stem (ES) cells made by therapeutic cloning via nuclear transfer, with the successful technique first reported by the lab of Shoukhrat Mitalipov at OHSU last year? How do they compare to induced pluripotent stem (iPS) cells or traditional ES cells made from IVF embryos? A new paper in Nature directly tackles these […]

Review of Mitalipov Nature paper: cloned ES cells vs iPS cells Read More »

Cool, encouraging new preclinical study on monkey iPS cells

monkey-iPSC-tumors

What happens if we start using induced pluripotent stem (iPS) cells clinically in humans? A cool new paper recently came out that gets us closer to being able to predict an answer. It’s an important question as iPS cell-derived cellular products are getting closer to clinical use. For example, the first iPS cell-based clinical trial

Cool, encouraging new preclinical study on monkey iPS cells Read More »

In cell Olympics iPS cells get gold, while STAP cells are too young to judge

If you are like me, you’ve managed to watch at least a bit of the Olympics the last few weeks. Sometimes I squeeze in a few minutes late at night while multi-tasking writing a grant. Other folks with more time on their hands are Olympics fanatics with gold medals, ice, and snow on the brain

In cell Olympics iPS cells get gold, while STAP cells are too young to judge Read More »

Masayo Takahashi Interview on iPS cells, clinical studies, & more

Masayo-Takahashi

In the interview below I talk with Dr. Masayo Takahashi, who is leading a team conducting the first ever in-human clinical study based on iPS cells. The work began with patient enrollment on Aug. 1, 2013 in Japan. Masaya Takahashi background 1. Can you tell us a bit about your background? As an M.D./Ph.D. and

Masayo Takahashi Interview on iPS cells, clinical studies, & more Read More »

Stem cell journal club: dishing on Nature paper on making iPS cells inside mice

What if you could reprogram cells inside of an organism to a different fate and, for instance, make IPS cells? We can, right? But when most of us think about making induced pluripotent stem (iPS) cells, we imagine it all happening in a little plastic dish in our labs or in our colleague’s labs, not

Stem cell journal club: dishing on Nature paper on making iPS cells inside mice Read More »

Stem cell field mostly taking a wait-and-see attitude toward all chemical reprogramming to make iPS cells

I recently did a poll on people’s reactions to the new paper reporting use an all-chemical approach to making iPS cells through cellular reprogramming. I got a good number of responses relatively quickly. The results so far suggest that by far most people think it is too soon to know the importance of this new

Stem cell field mostly taking a wait-and-see attitude toward all chemical reprogramming to make iPS cells Read More »

Janet Rossant, ISSCR President, on her goals, cloning, non-compliant clinics, iPS cells, and future of field

New ISSCR President, Dr. Janet Rossant, kindly agreed to do an interview with me focused on the future of ISSCR, her plans for her tenure, and some key issues in the field. Dr. Rossant is Chief of Research at The Hospital for Sick Children in Toronto. 1. The stem cell arena is a very rapidly changing one

Janet Rossant, ISSCR President, on her goals, cloning, non-compliant clinics, iPS cells, and future of field Read More »

Perspectives on human micro-liver-like structures made from iPS cells

The big stem cell buzz the last day or two has been the news exploding across mainstream media outlets about laboratory-produced human livers grown from stem cells. It’s good news to be sure as it would seem we might be one important step closer to a new reality for millions of people suffering from liver disease.

Perspectives on human micro-liver-like structures made from iPS cells Read More »

Asahi Shimbun Editorial: iPS Cells Rushed For Economic Reasons

In a shocker, Japan’s 2nd largest newspaper, Asahi Shimbun, published an editorial yesterday  saying that iPS cells are being pushed too fast to the clinic for economic reasons. The piece was bluntly entitled “Too much of a rush for clinical trials with iPS cells”. Asahi Shimbun, with a circulation of 10 million, is taking a bold

Asahi Shimbun Editorial: iPS Cells Rushed For Economic Reasons Read More »